Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a clinical-stage biopharmaceutical company pioneering monoclonal antibody (mAb) therapies to combat evolving viral threats like COVID-19. This page provides investors and stakeholders with timely updates on Invivyd’s regulatory milestones, clinical trial progress, and strategic initiatives.
Discover the latest developments for PEMGARDA™, Invivyd’s EUA-authorized pre-exposure prophylaxis, and next-generation candidates like VYD2311. Our news collection covers critical updates including FDA communications, partnership announcements, and peer-reviewed data publications. All content is vetted for accuracy and relevance to ensure you stay informed on Invivyd’s progress in protecting immunocompromised populations.
Key focus areas include advancements from the proprietary INVYMAB™ platform, trial results demonstrating variant resistance, and manufacturing scalability updates. Bookmark this page for direct access to press releases, earnings call summaries, and analyses of Invivyd’s role in infectious disease innovation.
Invivyd, Inc. (Nasdaq: IVVD) announced the departure of its Chief Scientific Officer, Laura Walker, Ph.D., who is leaving to pursue other opportunities. Lukas Dillinger, Ph.D., has been appointed interim Head of Discovery and Pre-Clinical during the search for a replacement. CEO David Hering expressed gratitude for Walker's contributions, which were essential in establishing the company's pipeline of antibody candidates against SARS-CoV-2. Invivyd focuses on developing antibodies for serious infectious diseases, particularly COVID-19, with ongoing efforts to advance its pipeline of antibody therapies.
Invivyd, Inc. (Nasdaq: IVVD) participated in an FDA-EMA workshop on December 15, 2022, focusing on SARS-CoV-2 monoclonal antibodies. The company's chief scientific officer, Laura Walker, Ph.D., presented alongside industry leaders to discuss strategies for accelerating antibody development amid evolving variants. The presentation underscored the unmet medical need for COVID-19 therapies and proposed data-driven policy changes to optimize development timelines. Invivyd's antibody technologies aim to provide superior protection against viral diseases, including COVID-19.
Invivyd, Inc. (Nasdaq: IVVD) has announced key management changes effective December 16, 2022. Jeremy Gowler has been appointed as the Chief Operating and Commercial Officer, bringing 20 years of biopharma experience, including leadership at Sandoz. Additionally, Pete Schmidt, previously Vice President of Clinical Research, has been promoted to Chief Medical Officer. The company aims to advance its monoclonal antibodies pipeline for COVID-19 and other respiratory diseases while streamlining operations following Dr. Ellie Hershberger's departure, who will provide consulting services.
Invivyd, a clinical-stage biopharmaceutical company (Nasdaq: IVVD), has announced a strategic partnership with Population Health Partners (PHP) aimed at improving the efficiency of its NVD200 clinical program and developing engineered antibodies for COVID-19. This collaboration will leverage PHP's expertise in clinical development and regulatory strategies, aligning Invivyd's capabilities with the evolving SARS-CoV-2 landscape.
Invivyd's NVD200 candidate, integrating adintrevimab, is set to enter clinical trials in Q1 2023, addressing the urgent need for effective treatments amid dwindling antibody effectiveness against emerging variants.
Invivyd (Nasdaq: IVVD) announced its third-quarter 2022 results, highlighting a cash position of $419 million, expected to fund operations into Q2 2024. The company aims to advance its monoclonal antibody candidate, NVD200, into clinical trials in Q1 2023. During the quarter, R&D expenses decreased to $34.1 million from $49.4 million in 2021, while SG&A expenses rose to $13.2 million. The net loss narrowed to $45.1 million from $60.4 million year-over-year, with a per-share loss of $0.42. A conference call is scheduled for November 10 at 4:30 p.m. ET.
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical firm, announced that CEO David Hering will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 4:25 p.m. GMT. The event will be accessible via a live webcast on the investor section of Invivyd’s website, with an archive available for 90 days post-presentation.
Invivyd focuses on developing antibodies to enhance immunity against serious viral respiratory diseases, including COVID-19. Its first candidate, NVD200, aims to prevent and treat COVID-19 using advanced antibody technology.
Invivyd, a clinical-stage biopharmaceutical company, announced a conference call to discuss its Q3 financial results on November 10, 2022, at 4:30 p.m. ET. The earnings report will cover the period ending September 30, 2022, alongside recent business highlights. Invivyd focuses on developing antibodies to combat viral respiratory diseases, notably COVID-19, with its candidate NVD200 showing promise. The company aims to enhance immunity against evolving viral threats. Analysts can join the Q&A session after the call.
Invivyd, Inc. (Nasdaq: IVVD) has appointed Christine Lindenboom, former senior vice president at Alnylam Pharmaceuticals, to its board of directors. Her extensive experience in healthcare and biopharmaceuticals is expected to enhance the company's strategic direction. Meanwhile, Redonda Miller, president of The Johns Hopkins Hospital, has stepped down from the board. Invivyd is focused on developing antibody solutions for viral diseases including COVID-19, with their first product, NVD200, anticipated to enter clinical trials in Q1 2023.
Invivyd (Nasdaq: IVVD) announced the appointment of Fred Driscoll as interim CFO, as part of a strategic restructuring to enhance capital efficiency and focus on key programs. The company is reallocating resources to support its integrated discovery platform and advance pipeline programs, particularly NVD200 for COVID-19 prevention and treatment. This transition follows the departure of Jane Pritchett Henderson and Eric Kimble, who are leaving to pursue other opportunities. An executive search for a permanent CFO and a business development executive is underway.
Invivyd (Nasdaq: IVVD) announced four poster presentations at ID Week 2022, showcasing findings from studies on adintrevimab. Key posters include:
- Poster 226: Higher Doses of Adintrevimab for COVID-19 treatment - Phase 1 preliminary results.
- Poster 591: Population Pharmacokinetics of Adintrevimab in clinical study participants.
- Poster 1113: Clinical outcomes with Early Adintrevimab Therapy in COVID-19.
- Poster 1132: Characterizing Viral Dynamics after Adintrevimab administration.
Adintrevimab remains investigational, showing promise against COVID-19 variants.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
